Improved adenoviral vectors: Cautious optimism for gene therapy

QJM: An International Journal of Medicine

Volumn 90, Issue 2, 1997, Pages 105-109

  Channon, K M ^a   George, S E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; GENE THERAPY; GENE TRANSFER; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031029415     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/90.2.105     Document Type: Short Survey

References (42)

1. Ali M, Lemoine NR, Ring CJA. The use of DNA viruses as vectors for gene therapy. Gene Therapy 1994; 1:367-84.
2. Horwitz MS. Adenoviridae and their replication. In: Fields BN, Knipe DM, eds. Virology, 2nd edn. New York, Raven Press, 1990:1679-721.
3. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther 1993; 4:403-9.
4. Barr E, Carroll J, Kalynych AM, Tripathy SK, Kozarsky K, Wilson JM, et al. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Therapy 1994; 1:51-8.
5. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993; 3:219-23.
6. Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, Conzalezgarcia M, et al. A recombinant bcl-x(s) adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc Natl Acad Sci USA 1995; 92:11024-8.
7. Nabel EG, Pompili VJ, Plautz GE, Nabel GJ. Gene transfer and vascular disease. Cardiovasc Res 1994; 28:445-55.
8. Channon KM, Blazing MA, George SE. Vascular gene transfer. Heart 1996; 85:215-17.
9. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90:2812-16.
10. Tripathy SK, Goldwasser E, Lu M-M, Barr E, Leiden JM. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus. Proc Natl Acad Sci USA 1994; 91:11557-61.
11. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265:781-4.
12. Simari RD, San H, Rekhter M, Ohno T, Gordon D, Nabel GJ, et al. Regulation of cellular proliferation and intimai formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 1996; 98:225-35.
13. Johnson LG, Boyles SE, Wilson J, Boucher RC. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995; 95:1377-82.
14. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68:143-55.
15. Crystal RG, McElvaney NG, Rosenfeld MA, Chu C-S, Mastrangeli A, Hay JG, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genetics 1994; 8:42-51.
16. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu P-C, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New Engl J Med 1995; 333:823-31.
17. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91:4407-11.
18. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69:2004-15.
19. Yang Y, Jooss KU, Su Q, Ertl HCJ, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3:137-44.
20. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995; 96:2955-65.
21. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Therapy 1996; 3:412-20.
22. Yei S, Mittereder N, Wert S, Whitsett JA, Wilmott RW, Trapnell BC. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Human Gene Therapy 1994; 5:731-44.
23. Schulick AH, Dong G, Virmani R, Dichek DA. Enodothelium-specific in-vivo gene transfer. Circulation Research 1995; 77:475-85.
24. Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries: Optimization and evaluation of acute toxicity. Circulation 1995; 91:2407-14.
25. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, Leinwand LA. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Therapy 1994; 1:395-402.
26. Lochmuller H, Petrof BJ, Allen C, Prescott S, Massie B, Karpati G. Immunosuppression by FK506 markedly prolongs expression of adenovirus-delivered transgene in skeletal muscles of adult dystrophic [mdx] mice. Biochem Biophys Res Commun 1995; 213:569-74.
27. Zsengeller ZK, Wert SE, Hull WM, Hu X, Yei S, Trapnell BC, et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Human Gene Therapy 1995; 6:457-67.
28. Kolls JK, Lei DH, Odom G, Nelson S, Summer WR, Gerber MA, et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Human Gene Therapy 1996; 7:489-97.
29. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Medicine 1995; 1:890-3.
30. Lee MG, Abina MA, Haddada H, Perricaudet M. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther 1995; 2:256-62.
31. Wang Q, Finer MH. Second-generation adenovirus vectors. Nature Medicine 1996; 2:714-16.
32. Bridge E, Medghalchi S, Ubol S, Leesong M, Ketner G. Adenovirus early region 4 and viral DNA synthesis. Virology 1993; 193:794-801.
33. Wang Q, Jia XC, Finer MH. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Therapy 1995; 2:775-83.
34. Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217:11-22.
35. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and b-galactosidase. Proc Natl Acad Sci USA 1996; 93:5731-6.
36. Krougliak V, Graham FL. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Human Gene Therapy 1995; 6:1575-86.
37. Engelhardt JF, Ye X, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A 1994; 91:6196-200.
38. Chen H, Ramachandra M, Padmanabhan R. Biochemical characterization of a temperature-sensitive adenovirus DNA polymerase. Virology 1994; 205:364-70.
39. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994; 5:1217-29.
40. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genetics 1994; 7:362-9.
41. Gao G-P, Yang Y, Wilson JM. Biology of adenoviral vectors deleted of E1 and E4 for liver-directed gene therapy. J Virol 1996; in press.
42. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Medicine 1996; 2:545-50.